Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Johnson & Johnson Pharmaceutical Research & Development, a subsidiary of Johnson & Johnson, has submitted a new drug application to the FDA for carisbamate, a new investigational compound for the adjunctive treatment of partial onset seizures in patients 16 years of age and older.
Subscribe to our email newsletter
The filing is supported by data from three placebo-controlled clinical trials in patients with epilepsy. Previously, Johnson & Johnson Pharmaceutical Research & Development (J&JPRD) and SK Holdings have previously entered into a license agreement to develop and commercialize carisbamate.
J&JPRD has received global marketing rights for the compound. If approved by the FDA, carisbamate will be marketed by Ortho-McNeil Neurologics, a division of Ortho-McNeil-Janssen Pharmaceuticals. Carisbamate has received provisional approval by the FDA to be marketed under the brand name of Comfyde.